Strut Health
Compare the published cost of each product and dose. Starting offers, maintenance prices, and membership fees can differ.
Loading offers…
Compare the published cost of each product and dose. Starting offers, maintenance prices, and membership fees can differ.
Loading offers…
Search by medication, provider or treatment goal. Examples follow.
Semaglutide · Compounded
1 offers · US self-pay
This order ignores commission. Partner links may earn us a referral fee.
Supply period unverified; excluded from cost ranking.
Checked
oral lozenge with auto-refill; weekly injection from $149 with auto-refill
No separate dose price verified
Strut now prescribes compounded GLP-1s only for patients who cannot use a commercially available GLP-1 (medical necessity required). The page states no supply length for these prices; final price is set after the consultation. Compounded; not FDA-approved.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price sourceRead prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.
Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.
The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.
Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.